I agree its all speculation at this point we do not know what the next several months hold. I too believe in management, but Id be lying if I said a 10:1 split for a company with no revenue or just starting to see a little revenue doesn't scare me a bit. I hope to see a JV partner with a good up front payment, id like to see proof that BP believes Lympro is a homerun (like I do at this point). Gerald did make it a point to say that if a RS was issued to uplist value building news would follow soon after. At this point I am just looking forward to LP002 data EOM.